Work

Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response

Year: 2025

Type: article

Study design: Observational Study

Source: Pigment Cell & Melanoma Research

DOI: 10.1111/pcmr.70023

Authors: Ethan Trim, Anita Giobbie‐Hurder, Tamara A. Sussman, David Liu, Megan Insco, Rizwan Haq, F. Stephen Hodi, Patrick A. Ott, Elizabeth I. Buchbinder

Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4411434402

FWCI:

Cites: 12

Cited by:

Related to: 10